MX2023003700A - Peptides and methods of use. - Google Patents

Peptides and methods of use.

Info

Publication number
MX2023003700A
MX2023003700A MX2023003700A MX2023003700A MX2023003700A MX 2023003700 A MX2023003700 A MX 2023003700A MX 2023003700 A MX2023003700 A MX 2023003700A MX 2023003700 A MX2023003700 A MX 2023003700A MX 2023003700 A MX2023003700 A MX 2023003700A
Authority
MX
Mexico
Prior art keywords
peptides
methods
synthetic
peptide
neutrophils
Prior art date
Application number
MX2023003700A
Other languages
Spanish (es)
Inventor
Neel K Krishna
Kenji Cunnion
Ulrich Thienel
Original Assignee
Realta Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Life Sciences Inc filed Critical Realta Life Sciences Inc
Publication of MX2023003700A publication Critical patent/MX2023003700A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides peptides that are synthetic modifications of Polar Assortant (PA) peptide including C -terminal PEGylation. The invention further provides methods of using least one synthetic peptide for regulating the complement system and interacting with neutrophils to alter their binding and activity.
MX2023003700A 2020-09-30 2021-09-27 Peptides and methods of use. MX2023003700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063085556P 2020-09-30 2020-09-30
US202163185831P 2021-05-07 2021-05-07
PCT/US2021/052174 WO2022072272A2 (en) 2020-09-30 2021-09-27 Peptides and methods of use

Publications (1)

Publication Number Publication Date
MX2023003700A true MX2023003700A (en) 2023-04-21

Family

ID=80951791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003700A MX2023003700A (en) 2020-09-30 2021-09-27 Peptides and methods of use.

Country Status (10)

Country Link
US (1) US20240010681A1 (en)
EP (1) EP4222168A2 (en)
JP (1) JP2023548001A (en)
KR (1) KR20230078733A (en)
AU (1) AU2021355358A1 (en)
BR (1) BR112023005783A2 (en)
CA (1) CA3193565A1 (en)
IL (1) IL301441A (en)
MX (1) MX2023003700A (en)
WO (1) WO2022072272A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009152944A1 (en) * 2008-05-29 2009-12-23 Hanall Pharmaceutical Co., Ltd Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
SG11202006063RA (en) * 2018-01-09 2020-07-29 Realta Holdings Llc Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Also Published As

Publication number Publication date
KR20230078733A (en) 2023-06-02
JP2023548001A (en) 2023-11-15
AU2021355358A1 (en) 2023-06-08
WO2022072272A2 (en) 2022-04-07
CA3193565A1 (en) 2022-04-07
WO2022072272A3 (en) 2022-05-12
EP4222168A2 (en) 2023-08-09
BR112023005783A2 (en) 2023-04-25
IL301441A (en) 2023-05-01
US20240010681A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
PH12020551391A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
PH12019500750A1 (en) Chimeric antigen receptors for the treatment of cancer
MX2020002596A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof.
SG10201908269SA (en) Modulation of tumor immunity by protein-mediated o2 delivery
NZ756763A (en) Engineered transferrin receptor binding polypeptides
MX2021006017A (en) Methods and compositions for treatment of disorders with follistatin polypeptides.
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2021014476A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof.
WO2018187356A3 (en) Protein antigens and uses thereof
MX2020007024A (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same.
MX2021004284A (en) Anti-npr1 antibodies and uses thereof.
EP4001310A3 (en) Ion channel modulators and uses thereof
MX2021015160A (en) Natriuretic peptide receptor 1 antibodies and methods of use.
MX2021007479A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof.
WO2018138032A3 (en) NKp46 BINDING AGENTS
MX2020007555A (en) Factor h potentiating antibodies and uses thereof.
MX2021006945A (en) Anellosomes for delivering protein replacement therapeutic modalities.
MX2022009100A (en) Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer.
ZA202107947B (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
MX2022005236A (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems.
MX2020012273A (en) Protein binding nkg2d, cd16 and a fibroblast activation protein.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
NZ710900A (en) Il-1β inhibitor composition and use thereof
MX2021005416A (en) Combination of chemotherapy with recombinant s. rolfsii lectin.
MX2023003700A (en) Peptides and methods of use.